RxDoctor Payments Data

Marc Veneziano, MD

Cardiovascular Disease · Cumming, GANPI 1740321041

Payments from drug & device makers

$771in general payments, 2019–2025

Across 39 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$158
  • Pfizer$84
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$73
  • Amgen$70
  • Boston Scientific$56
  • Heartflow, Inc.$47
  • plus $284 from 11 others

What the payments were for

  • Food & beverage$771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$771 in reported general payments places this provider in the 30th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$410,989
Medicare patients
1,066
Services billed
5,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban491$428,743
XareltoRivaroxaban130$138,051
Repatha SureclickEvolocumab58$45,686
EntrestoSacubitril/Valsartan47$43,636
BrilintaTicagrelor34$24,826
FarxigaDapagliflozin Propanediol17$8,280
Metoprolol Succinate542$5,473
Ranolazine ErRanolazine73$4,547
Dabigatran EtexilateDabigatran Etexilate Mesylate24$3,791
Enoxaparin Sodium12$3,748
Propafenone Hcl ErPropafenone Hcl14$3,445
Hydralazine Hcl265$3,269
Carvedilol603$2,710
Diltiazem 24hr Er (Cd)Diltiazem Hcl219$2,659
Midodrine Hcl45$2,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$428,743491 claims
Johnson & JohnsonXarelto$16$138,051130 claims
NovartisEntresto$158$43,63647 claims
AstraZenecaBrilinta, Farxiga$31$33,10651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →